MRTX Mirati Therapeutics Inc.

72.01
-4.86  -6%
Previous Close 76.87
Open 74.92
Price To Book 8.19
Market Cap 3,131,023,748
Shares 43,480,402
Volume 501,723
Short Ratio
Av. Daily Volume 511,801
Stock charts supplied by TradingView

NewsSee all news

  1. Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates

    SAN DIEGO, Feb. 25, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full year-ended December 31,

  2. Mirati Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Feb. 19, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical stage targeted oncology company, today announced the grants of inducement non-qualified stock options to purchase an aggregate

  3. Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Syposium

    SAN DIEGO, Feb. 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from an ongoing investigator sponsored Phase

  4. Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

    SAN DIEGO, Jan. 14, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX) today announced the closing of its previously announced underwritten public offering of 3,538,462 shares of its common stock at a public

  5. Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

    SAN DIEGO, Jan. 9, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX) today announced the pricing of an underwritten public offering of 3,076,924 shares of its common stock at a price to the public of $97.50

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 update at SITC November 2018 - 5/29 partial responses.
Mocetinostat and durvalumab
Non-small cell lung cancer (NSCLC)
Phase 2 updated data presented at ASCO GU 2020. 15/38 (39%) partial response rate, PFS 10.3 months - February 15, 2020.
Sitravatinib and Nivolumab
Renal cell carcinoma (RCC)
Phase 3 interim analysis 4Q 2021.
Sitravatinib plus nivolumab
Non-small cell lung cancer (NSCLC)
Phase 1 data noted ORR 23.5% - December 13, 2019.
Sitravatinib and tislelizumab
Ovarian cancer
Phase 1/2 updated data due 2H 2020.
MRTX849
Solid tumors
Phase 2 initial data presented at SITC November 9, 2019 noted 6/22 ORR, 21/22 SD.
Sitravatinib
Urothelial Carcinoma (Bladder)

Latest News

  1. Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates

    SAN DIEGO, Feb. 25, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full year-ended December 31,

  2. Mirati Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Feb. 19, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical stage targeted oncology company, today announced the grants of inducement non-qualified stock options to purchase an aggregate

  3. Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Syposium

    SAN DIEGO, Feb. 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from an ongoing investigator sponsored Phase

  4. Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

    SAN DIEGO, Jan. 14, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX) today announced the closing of its previously announced underwritten public offering of 3,538,462 shares of its common stock at a public

  5. Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

    SAN DIEGO, Jan. 9, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX) today announced the pricing of an underwritten public offering of 3,076,924 shares of its common stock at a price to the public of $97.50

  6. Mirati Therapeutics Announces Proposed Public Offering of Common Stock

    SAN DIEGO, Jan. 8, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX) today announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common

  7. Mirati Therapeutics Announces Executive Management Changes

    SAN DIEGO, Jan. 6, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical stage targeted oncology company, today announced changes to their executive management team, effective immediately. Mirati

  8. Mirati Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference

    SAN DIEGO, Jan. 2, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical stage targeted oncology company, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday,

  9. Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting

    SAN DIEGO, Nov. 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of

  10. Mirati Therapeutics Reports Third Quarter 2019 Financial Results

    SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2019. Recent

  11. Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting

    SAN DIEGO, Oct. 23, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, announced that the Company will have two presentations at the Society for Immunotherapy of